Vancomycin-resistant enterococcus - A review from a Singapore perspective

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 10, 2008, Pages 861-869

  Chlebicki, Maciej Piotr ^a   Kurup, Asok ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Antibiotic resistance; Infection control; Outbreaks; Surveillance

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ARTHRALGIA; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; BONE MARROW SUPPRESSION; DRUG COST; EPIDEMIC; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE INFLAMMATION; MYALGIA; NONHUMAN; REVIEW; SEROTONIN SYNDROME; SINGAPORE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 56449114853     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Mundt JO. Occurrence of enterococci in animals in a wild environment. Appl Microbiol 1963;11:136-40.
2. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 1998;4:239-49.
3. Bonten MJ, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996;348:1615-9.
4. Neely AN, Maley MP. Survival of enterococci and staphylococci on hospital fabrics and plastic. J Clin Microbiol 2000;38:724-6.
5. Moellering RC Jr. Enterococcus species, Streptococcus bovis and Leuconostoc species. In: Mandel GL, Bennett JE, Dolin R, editor. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier, 2005:2411-21.
6. Goetz AM, Rihs JD, Wagener MM, Muder RR. Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey. Am J Infect Control 1998;26:558-62.
7. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and - susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000;36:145-58.
8. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522-7.
9. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002;28:692-7.
10. Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127-33.
11. Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg 1997;132:76-81.
12. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-23.
13. Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993-1000.
14. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58:163-70.
15. Bell JM, Paton JC, Turnidge J. Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol 1998;36:2187-90.
16. Christiansen KJ, Tibbett PA, Beresford W, Pearman JW, Lee RC, Coombs GW, et al. Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 2004;25:384-90.
17. Koh TH, Hsu LY, Chiu LL, Lin RV. Emergence of epidemic clones of vancomycin-resistant Enterococcus faecium in Singapore. J Hosp Infect 2006;63:234-6.
18. Zirakzadeh A, Patel R. Epidemiology and mechanisms of glycopeptide resistance in enterococci. Curr Opin Infect Dis 2005;18:507-12.
19. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7.
20. Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB. Vancomycin-resistant Staphylococcus aureus associated with Inc18-like vanA plasmids in Michigan. Antimicrob Agents Chemother 2008;52:452-7.
21. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006;12 Suppl 1:16-23.
22. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.
23. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
24. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32 Suppl 2:S133-S145.
25. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
26. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
27. Ang SW, Seah CS, Lee ST. Vancomycin-resistant enterococcus in the Singapore National Burns Centre: a case report. Ann Acad Med Singapore 1996;25:270-2.
28. Chlebicki MP, Ling ML, Koh TH, Hsu LY, Tan BH, How KB, et al. First outbreak of colonization and infection with vancomycin-resistant Enterococcus faecium in a tertiary care hospital in Singapore. Infect Control Hosp Epidemiol 2006;27:991-3.
29. Yang KS, Fong YT, Lee HY, Kurup A, Koh TH, Koh D, et al. Predictors of vancomycin-resistant enterococcus (VRE) carriage in the first major VRE outbreak in Singapore. Ann Acad Med Singapore 2007;36:379-83.
30. Hsu LY, Tan TY, Jureen R, Koh TH, Krishnan P, Tzer-Pin Lin R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis 2007;13:1944-7.
31. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996;40:2605-9.
32. Thal LA, Chow JW, Mahayni R, Bonilla H, Perri MB, Donabedian SA, et al. Characterization of antimicrobial resistance in enterococci of animal origin. Antimicrob Agents Chemother 1995;39:2112-5.
33. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001;1:314-25.
34. Sorensen TL, Blom M, Monnet DL, Frimodt-Moller N, Poulsen RL, Espersen F. Transient intestinal carriage after ingestion of antibioticresistant Enterococcus faecium from chicken and pork. N Engl J Med 2001;345:1161-6.
35. van den Bogaard AE, Bruinsma N, Stobberingh EE. The effect of banning avoparcin on VRE carriage in The Netherlands. J Antimicrob Chemother 2000;46:146-8.
36. Aarestrup FM, Seyfarth AM, Emborg HD, Pedersen K, Hendriksen RS, Bager F. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother 2001;45:2054-9.
37. Lim SK, Kim TS, Lee HS, Nam HM, Joo YS, Koh HB. Persistence of vanA-type Enterococcus faecium in Korean livestock after ban on avoparcin. Microb Drug Resist 2006;12:136-9.
38. Lauderdale TL, Shiau YR, Wang HY, Lai JF, Huang IW, Chen PC, et al. Effect of banning vancomycin analogue avoparcin on vancomycin-resistant enterococci in chicken farms in Taiwan. Environ Microbiol 2007;9:819-23.
39. Radu S, Toosa H, Rahim RA, Reezal A, Ahmad M, Hamid AN, et al. Occurrence of the vanA and vanC2/C3 genes in Enterococcus species isolated from poultry sources in Malaysia. Diagn Microbiol Infect Dis 2001;39:145-53.
40. Tanimoto K, Nomura T, Hamatani H, Xiao YH, Ike Y. A vancomycin-dependent VanA-type Enterococcus faecalis strain isolated in Japan from chicken imported from China. Lett Appl Microbiol 2005;41:157-62.
41. Polgreen PM, Beekmann SE, Chen YY, Doern GV, Pfaller MA, Brueggemann AB, et al. Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus in a rural state. Infect Control Hosp Epidemiol 2006;27:252-6.
42. Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 2001;7:183-7.
43. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-72.
44. Karanfil LV, Murphy M, Josephson A, Gaynes R, Mandel L, Hill BC, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
45. Wade JJ. The emergence of Enterococcus faecium resistant to glycopeptides and other standard agents - a preliminary report. J Hosp Infect 1995;30Suppl:483-93.
46. Morris JG Jr, Shay DK, Hebden JN, McCarter RJ Jr, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9.
47. Papanicolaou GA, Meyers BR, Meyers J, Mendelson MH, Lou W, Emre S, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996;23:760-6.
48. Roghmann MC, Fink JC, Polish L, Maker T, Brewrink J, Morris JG Jr, et al. Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney Dis 1998;32:254-7.
49. Slaughter S, Hayden MK, Nathan C, Hu TC, Rice T, Van Voorhis J, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996;125:448-56.
50. Rao GG, Ojo F, Kolokithas D. Vancomycin-resistant gram-positive cocci: risk factors for faecal carriage. J Hosp Infect 1997;35:63-9.
51. Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, Nathan C, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998;158:1127-32.
52. Dever LL, China C, Eng RH, O'Donovan C, Johanson WG Jr. Vancomycin-resistant Enterococcus faecium in a Veterans Affairs Medical Center: association with antibiotic usage. Am J Infect Control 1998;26:40-6.
53. Beltrami EM, Singer DA, Fish L, Manning K, Young S, Banerjee SN, et al. Risk factors for acquisition of vancomycin-resistant enterococci among patients on a renal ward during a community hospital outbreak. Am J Infect Control 2000;28:282-5.
54. Padiglione AA, Wolfe R, Grabsch EA, Olden D, Pearson S, Franklin C, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother 2003;47:2492-8.
55. Loeb M, Salama S, Armstrong-Evans M, Capretta G, Olde J. A case-control study to detect modifiable risk factors for colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1999;20:760-3.
56. Ostrowsky BE, Venkataraman L, D'Agata EM, Gold HS, DeGirolami PC, Samore MH. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999;159:1467-72.
57. Tokars JI, Satake S, Rimland D, Carson L, Miller ER, Killum E, et al. The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans' Affairs institution. Infect Control Hosp Epidemiol 1999;20:171-5.
58. Garbutt JM, Littenberg B, Evanoff BA, Sahm D, Mundy LM. Enteric carriage of vancomycin-resistant Enterococcus faecium in patients tested for Clostridium difficile. Infect Control Hosp Epidemiol 1999;20:664-70.
59. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834-44.
60. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-32.
61. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:1055-61.
62. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 1999;159:2461-8.
63. DeLisle S, Perl TM. Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance. Chest 2003;123:504S-18S.
64. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362-86.
65. Wendt C, Wiesenthal B, Dietz E, Ruden H. Survival of vancomycin-resistant and vancomycin-susceptible enterococci on dry surfaces. J Clin Microbiol 1998;36:3734-6.
66. Wong AH, Wenzel RP, Edmond MB. Epidemiology of bacteriuria caused by vancomycin-resistant enterococci - a retrospective study. Am J Infect Control 2000;28:277-81.
67. Quale J, Landman D, Atwood E, Kreiswirth B, Willey BM, Ditore V, et al. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996;24:372-9.
68. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.
69. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
70. Landry SL, Kaiser DL, Wenzel RP. Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control 1989;17:323-9.
71. Wells CL, Juni BA, Cameron SB, Mason KR, Dunn DL, Ferrieri P, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995;21:45-50.
72. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003;51 Suppl 3:iii23-30.
73. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 2006;81:529-36.
74. Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006;6:486-90.
75. Linden PK, Moellering RC Jr, Wood CA, Rehm SJ, Flaherty J, Bompart F, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:1816-23.
76. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007;28:632-45.
77. Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006;26:1784-93.
78. Ziglam H. Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opin Pharmacother 2007;8:2279-92.
79. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995;16:105-13.
80. Byers KE, Anglim AM, Anneski CJ, Germanson TP, Gold HS, Durbin LJ, et al. A hospital epidemic of vancomycin-resistant enterococcus: risk factors and control. Infect Control Hosp Epidemiol 2001;22:140-7.
81. Ostrowsky BE, Trick WE, Sohn AH, Quirk SB, Holt S, Carson LA, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001;344:1427-33.
82. Siddiqui AH, Harris AD, Hebden J, Wilson PD, Morris JG Jr, Roghmann MC. The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. Am J Infect Control 2002;30:40-3.
83. Montecalvo MA, de Lencastre H, Carraher M, Gedris C, Chung M, VanHorn K, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680-5.
84. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002;23:429-35.
85. D'Agata EM, Gautam S, Green WK, Tang YW. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002;34:167-72.
86. Landman D, Quale JM, Oydna E, Willey B, Ditore V, Zaman M, et al. Comparison of five selective media for identifying fecal carriage of vancomycin-resistant enterococci. J Clin Microbiol 1996;34:751-2.
87. Taylor ME, Oppenheim BA, Chadwick PR, Weston D, Palepou MF, Woodford N, et al. Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens. J Hosp Infect 1999;43:25-32.
88. Mascini EM, Bonten MJ. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin Microbiol Infect 2005;11 Suppl 4:43-56.
89. Koh TH, Deepak RN, Se-Thoe SY, Lin RV, Koay ES. Experience with the Roche LightCycler VRE detection kit during a large outbreak of vanB2/B3 vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 2007;60:182-3.
90. Young HL, Ballard SA, Roffey P, Grayson ML. Direct detection of vanB2 using the Roche LightCycler vanA/B detection assay to indicate vancomycin-resistant enterococcal carriage - sensitive but not specific. J Antimicrob Chemother 2007;59:809-10.
91. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol 2007;28:249-60.
92. Perencevich EN, Fisman DN, Lipsitch M, Harris AD, Morris JG Jr, Smith DL. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004;38:1108-15.
93. Burke JF, Quinby WC, Bondoc CC, Sheehy EM, Moreno HC. The contribution of a bacterially isolated environment to the prevention of infection in seriously burned patients. Ann Surg 1977;186:377-87.
94. Klein BS, Perloff WH, Maki DG. Reduction of nosocomial infection during pediatric intensive care by protective isolation. N Engl J Med 1989;320:1714-21.
95. Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 1995;9:497-530.
96. Cunha BA. Antibiotic resistance. Control strategies. Crit Care Clin 1998;14:309-27.
97. Finkelstein JA, Davis RL, Dowell SF, Metlay JP, Soumerai SB, Rifas-Shiman SL, et al. Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics 2001;108:1-7.
98. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997;103:51-9.
99. Arnold FW, McDonald LC, Smith RS, Newman D, Ramirez JA. Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians. Infect Control Hosp Epidemiol 2006;27:378-82.
100. Pelletier LL Jr. Hospital usage of parenteral antimicrobial agents: a gradated utilization review and cost containment program. Infect Control 1985;6:226-30.
101. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. Arch Intern Med 2003;163:972-8.
102. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441-6.
103. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45 Suppl 2:S112-21.
104. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-9.
105. Apisarnthanarak A, Danchaivijitr S, Khawcharoenporn T, Limsrivilai J, Warachan B, Bailey TC, et al. Effectiveness of education and an antibiotic-control program in a tertiary care hospital in Thailand. Clin Infect Dis 2006;42:768-75.
106. Chang MT, Wu TH, Wang CY, Jang TN, Huang CY. The impact of an intensive antimicrobial control program in a Taiwanese medical center. Pharm World Sci 2006;28:257-64.
107. Lee SO, Lee ES, Park SY, Kim SY, Seo YH, Cho YK. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004;25:832-7.
108. Montecalvo MA, Jarvis WR, Uman J, Shay DK, Petrullo C, Rodney K, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131:269-72.
109. Belliveau PP, Rothman AL, Maday CE. Limiting vancomycin use to combat vancomycin-resistant Enterococcus faecium. Am J Health Syst Pharm 1996;53:1570-5.
110. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-7.
111. Yates RR. New intervention strategies for reducing antibiotic resistance. Chest 1999;115:24S-27S.
112. Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998;338:232-8.
113. Paul M, Andreassen S, Tacconelli E, Nielsen AD, Almanasreh N, Frank U, et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother 2006;58:1238-45.
114. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996;124:884-90.
115. Boyce JM. Vancomycin-resistant enterococci: pervasive and persistent pathogens. Infect Control Hosp Epidemiol 1995;16:676-9.
116. Lai KK, Fontecchio SA, Kelley AL, Melvin ZS, Baker S. The epidemiology of fecal carriage of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1997;18:762-5.
117. Hachem R, Raad I. Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2002;23:43-4.
118. Mondy KE, Shannon W, Mundy LM. Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2001;33:473-6.
119. Weinstein MR, Dedier H, Brunton J, Campbell I, Conly JM. Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1999;29:361-6.
120. Baden LR, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold HS, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance". Clin Infect Dis 2001;33:1654-60.
121. Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT. Recurrence of vancomycin-resistant enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002;23:436-40.
122. Henning KJ, Delencastre H, Eagan J, Boone N, Brown A, Chung M, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:848-54.
123. Chiew YF, Ling ML. Two cases of vancomycin-resistant enterococci from Singapore. J Infect 1998;36:133-4.
124. Oon LL, Ling MM, Chiew YF. Gastrointestinal colonisation of vancomycin-resistant enterococcus in a Singapore teaching hospital. Pathology 2001;33:216-21.
125. Fisher DA, Lin R, Chai L, Kumarasinghe G, Singh K, Tambyah PA. Vancomycin-resistant enterococci in a Singapore teaching hospital prior to 2005. Singapore Med J 2005;46:311-2.
126. Kurup A, Chlebicki MP, Ling ML, Koh TH, Tan KY, Lee LC, et al. Control of a hospital-wide vancomycin-resistant enterococci outbreak. Am J Infect Control 2008;36:206-11.
127. Willems RJ, Top J, van Santen M, Robinson DA, Coque TM, Baquero F, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005;11:821-8.
128. Tay JK, Bodle EE, Fisher DA, Lin RV, Kumarasinghe G, Tambyah PA. Screening for vancomycin-resistant enterococci using stools sent for Clostridium difficile cytotoxin assay is effective: results of a survey of 300 patients in a large Singapore teaching hospital. Ann Acad Med Singapore 2007;36:926-4.